9H-fluoren-9-yl 4-[[8-[[(1R,3S)-3-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl]-methylamino]-8-oxooctyl]amino]-4-oxobutanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 9H-fluoren-9-yl 4-[[8-[[(1R,3S)-3-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl]-methylamino]-8-oxooctyl]amino]-4-oxobutanoate
• 化学式: C₄₁H₄₂Cl₂N₂O₄
• 分子量: 697.7
• InChiKey: UKNFOLASVQYRGI-PIZIKKFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  49
• 可旋转键数：
  15
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  75.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Compositions and Methods for the Treatment of Parkinson Disease by the Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
  申请人：nLife Therapeutics, S.L.

  公开号：US20140120158A1

  公开（公告）日：2014-05-01

  The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is α-synuclein or the mRNA encoding α-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
• US9084825B2
  申请人：——

  公开号：US9084825B2

  公开（公告）日：2015-07-21
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON DISEASE BY THE SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON PAR ADMINISTRATION SÉLECTIVE DE MOLÉCULES D'OLIGONUCLÉOTIDES À DES TYPES SPÉCIFIQUES DE NEURONES
  申请人：NLIFE THERAPEUTICS S L

  公开号：WO2014064257A1

  公开（公告）日：2014-05-01

  The invention provides a conjugate comprising(i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonine transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is α-synuclein or the mRNA encoding α-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.